Answers are grounded in this paper and cite their sources.
Current management follows standard guidelines; leaves open whether phenotype-matched neuroimmune interventions improve stroke-heart syndrome outcomes.
This review examines the mechanisms, clinical phenotypes, diagnosis, and management of stroke–heart syndrome (SHS), defined as new or worsening cardiac dysfunction within 30 days after stroke. We focus on acute ischaemic stroke and consider intracerebral and subarachnoid haemorrhage separately. Human studies show that SHS is common and begins early: in VISTA, its incidence was 11.8%, median onset was on day 2, and delayed SHS was associated with higher 90-day mortality. Experimental studies implicate interacting autonomic, neuroendocrine, inflammatory, metabolic, and multi-organ pathways, including sympathetic activation, NLRP3/AIM2 inflammasome signalling, and splenic and bone-marrow immune relays. We propose the context-dependent neuroimmune circuit framework to generate testable hypotheses about how timing and anatomical compartment shape these responses. Clinically, troponin elevation should be interpreted together with serial measurements, ECG, echocardiography, symptoms when assessable, and neurological status. Management currently follows established stroke and cardiovascular indications because no SHS-specific therapy has been proven effective. Future studies should validate overlapping mechanism-based phenotypes and test phenotype-matched interventions in SHS-specific randomised trials.
No takes yet. Share an insight, caveat, or question.
Ge et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: